Ustekinumab in the Treatment of Erythema Nodosum with Underlying Crohn’s Disease: A Case Report

Main Article Content

Antonio Sanín-Guana
Mark G. Lebwohl

Keywords

crohn's disease, ustekinumab, erythema nodosum

Abstract

Erythema nodosum (EN) is a septal panniculitis characterized by raised, tender, red or purple lesions with a diameter of 1-5 cm. It is commonly treated with corticosteroids and can be an extra-intestinal manifestation of Crohn’s disease (CD). CD can be treated with ustekinumab, a monoclonal antibody that targets the p-40 subunit of the interleukin-12 (IL-12) and interleukin-23 (IL-23). A 78-year-old woman with erythema nodosum and Crohn’s disease presented with multiple erythematous nodules, which had been recurring on both of her legs for decades. The patient had failed many traditional EN treatments and was prescribed off-label ustekinumab, resulting in resolution of EN. This finding  suggests that ustekinumab may be a potential treatment for EN in patients who also have CD. 

References

1. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. Am Fam Physician. 2011;84(12):1365-1375.

2. Jumani L, Kataria D, Ahmed MU, Shah MAA, Raja K, Shaukat F. The Spectrum of Extra-intestinal Manifestation of Crohn's Disease. Cureus. 2020;12(2):e6928. Published 2020 Feb 10. doi:10.7759/cureus.6928

3. Annese V. A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease. Saudi J Med Med Sci. 2019;7(2):66-73. doi:10.4103/sjmms.sjmms_81_18

4. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982-1992. doi:10.1097/MIB.0000000000000392

5. Fleisher M, Marsal J, Lee SD, et al. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(4):825-833. doi:10.1007/s10620-018-4971-1

6. Weinstein M, Turner D, Avitzur Y. Erythema nodosum as a presentation of inflammatory bowel disease. CMAJ. 2005;173(2):145-146. doi:10.1503/cmaj.050201

7. Faulkes RE. Upper limb erythema nodosum: the first presentation of Crohn's disease. Clin Case Rep. 2014;2(5):183-185. doi:10.1002/ccr3.87

8. Chowaniec M, Starba A, Wiland P. Erythema nodosum - review of the literature. Reumatologia. 2016;54(2):79-82. doi:10.5114/reum.2016.60217

9. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016;375(20):1946-1960. doi:10.1056/NEJMoa1602773

10. Globig AM, Sommer NP, Wild K, et al. Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease. Cell Mol Gastroenterol Hepatol. 2021;11(1):1-12. doi:10.1016/j.jcmgh.2020.07.005

11. Ustekinumab. Package insert. Janssen Pharmaceutical Companies; 2020.

12. Spagnuolo R, Dastoli S, Silvestri M, et al. Anti-interleukin 12/23 in the treatment of erythema nodosum and Crohn disease: A case report. Dermatol Ther. 2019;32(2):e12811. doi:10.1111/dth.12811

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>